Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight ...

CouponFollow Extension

6%
OFF

Eli Lilly Cuts Q4 Sales Forecast: ETFs To Buy On The Dip

2 weeks from now

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight ...

yahoo.com

5%
OFF

Eli Lilly Cuts Q4 Sales Forecast: ETFs To Buy On The Dip

2 weeks from now

Jan 15, 2025 · Of these, Eli Lilly takes the top spot, accounting for a 23.5% share. iShares U.S. Pharmaceuticals ETF has $603.5 million in AUM and charges 39 bps in fees and expenses. …

zacks.com

6%
OFF

Eli Lilly Cuts Q4 Sales Forecast: ETFs To Buy On The Dip - Barchart.com

2 weeks from now

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight …

barchart.com

5%
OFF

Eli Lilly Cuts Q4 Sales Forecast: ETFs To Buy On The Dip

2 weeks from now

Jan 15, 2025 · Of these, Eli Lilly takes the top spot, accounting for a 23.5% share. iShares U.S. Pharmaceuticals ETF has $603.5 million in AUM and charges 39 bps in fees and expenses. …

tradingview.com

$61
OFF

Eli Lilly Cuts Q4 Forecast Amid Weak Sales But Sees Bright 2025 …

2 weeks from now

ETF Report. Options 101. ... Upgrade to Premium. Eli Lilly Cuts Q4 Forecast Amid Weak Sales but Sees Bright 2025 with $61B Revenue Potential. Muslim Farooque . Tue, Jan 14, 2025, …

yahoo.com

6%
OFF

Eli Lilly Cuts Q4 Sales Forecast: ETFs To Buy On The Dip - Statfolio

2 weeks from now

Jan 15, 2025 · Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales... Zacks · via Yahoo Finance 15 Jan 2025 Eli Lilly: BofA says buy the dip …

statfolio.net

6%
OFF

Eli Lilly Stock Tumbles After New Forecasts Show Weight-loss Drug …

2 weeks from now

Jan 14, 2025 · Eli Lilly shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations.Lilly …

yahoo.com

6%
OFF

Eli Lilly Cuts Q4 Sales Forecast: ETFs To Buy On The Dip - MSN

2 weeks from now

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight ...

msn.com

6%
OFF

Eli Lilly: BofA Says Buy The Dip After Shares Slide On Q4 Miss

2 weeks from now

Jan 14, 2025 · Eli Lilly and Company (NYSE: LLY) shares slid 6.6% to $744.91, after it said it expects Q4 revenue at $13.5 billion- weaker than street expectations of $14.08 billion. The …

investing.com

5%
OFF

Eli Lilly Cuts Q4 Sales Forecast, But Analyst Remains Bullish On

2 weeks from now

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 million below the low end of the company’s prior guidance and ...

msn.com

6%
OFF

Eli Lilly Cuts Q4 Sales Forecast: ETFs To Buy On The Dip

2 weeks from now

LLY - Free Report) dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight …

newsbreak.com

$58
OFF

Eli Lilly Stock Jumps, Reversing Early Losses, After Weight-Loss ...

2 weeks from now

1 day ago · For 2025, Lilly expects $58 billion to $61 billion in sales and adjusted earnings of $22.50 to $24 per share. The midpoints of Eli Lilly's outlook topped analysts' forecast.

investors.com

7%
OFF

Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight

2 weeks from now

Shares of Eli Lilly & Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the stock’s worst day since March 15, 2021. The decline followed a ...

msn.com

$16.10
OFF

Why Eli Lilly Is A No-Brainer Stock To Buy On The Dip - MSN

2 weeks from now

Here's why Eli Lilly is a no-brainer stock to buy on the dip. ... Lilly cut its adjusted earnings per share forecast from between $16.10 and $16.60 to between $13.02 and $13.52, a reduction of …

msn.com

FAQs about Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip Coupon?

Will Eli Lilly report full quarterly results in 2025?

The drugmaker expects to report full quarterly results on Feb. 6 (see: all the Healthcare ETFs here). The company offered a bullish outlook for 2025. Heading into fiscal 2025, CEO David Ricks said Eli Lilly expects sales of weight-loss drugs to continue growing. ...

Is Eli Lilly's fourth-quarter revenue forecast too low?

Citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro, Eli Lilly (NYSE:LLY) revised its fourth-quarter revenue projection downward. Now estimating Q4 revenue at $13.5 billion, the company's projection falls short of analyst predictions of $13.96 billion. ...

Why did Eli Lilly drop 66%?

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro. However, the drugmaker offered solid guidance for 2025, underscoring the strong growth prospects. ...

Why did Eli Lily's shares fall sharply on Tuesday?

Investing.com-- Eli Lily’s shares fell sharply on Tuesday after the pharmaceutical company posted weaker-than-expected fourth quarter revenue, although BofA analysts said this presented a buying opportunity. ...

What drove Lilly's fourth quarter growth?

In the fourth quarter, top-line growth is expected to have been driven by demand growth for Lilly’s FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. However, in mid-January, Lilly lowered its sales guidance for full-year 2024 and announced disappointing preliminary sales numbers for the fourth quarter. ...

Will Lilly produce more incretins in 2025?

Lilly expects to produce at least 60% more salable doses of incretins in the first half of 2025 compared to last year. An update is expected on the fourth-quarter conference call. The Zacks Consensus Estimate for Mounjaro and Zepbound is pegged at $3.88 billion and $2.04 billion, respectively. ...